Loading...

MLYS MINERALYS THERAPEUTICS INC Product Launches 8-K Filing

MNRL

MLYS

MINERALYS THERAPEUTICS INC

(MLYS)

2025 8-K

Financial Results Announcement

FDA NDA Acceptance

Corporate Update

Financial Update

Stock Offering Details

Termination Notice

Product Expansion

Financial Statements

Financial Results

Trial Enrollment Complete

Financial Results

Trial Enrollment Complete

Trial Enrollment Complete

Financial Results

Appointment and Resignation

Clinical Trials Update

Earnings Report

Departure of Directors

Equity Offering

Private Placement

Appointment of Chief Busine...

Announcement of Launch-HTN ...

Data Presentation

Financial Results Announcement

Resignation and Appointments

Financial Results Announcement

Expansion of Phase 2 Trial

Earnings Report

Departure of Directors or C...

Financial Results Announcement

Amended Certificate and Bylaws

External Links:

On March 29, 2025, Mineralys Therapeutics, Inc. announced positive results from the Advance-HTN trial of lorundrostat, showing significant reductions in blood pressure for patients with uncontrolled hypertension. The trial demonstrated a favorable safety profile with low rates of serious adverse events.

AI Assistant

MINERALYS THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.